A retrospective mutation analysis of the ctDNA of 75 patients with SCHNC (stages I–IV, stage IV 62.7%) demonstrated that both overall ctDNA alterations and TP53 mutations significantly correlated with advanced tumor progression status and OS [31]. This evidence concerns the gene TP53 and neoplasm.